All the latest news and updates from Medovate.


Medovate Silver Sponsors of RA-UK Annual Scientific Meeting 2021

21st April, 2021

Medovate are delighted to be a Silver Sponsor of the RA-UK Annual Scientific Meeting 2021, which is taking place on Wednesday 5th – Thursday 6th May 2021. Regional Anaesthesia - UK (RA-UK) have announced that, due to ongoing coronavirus restrictions, the event this year will be delivered virtually in a dynamic format. The two-day conference will be filmed in a TV style production and broadcast live from a venue in Sheffield.


REPLAY: Mitigating for Nerve Injury - patient safety and cost optimisation in regional anaesthesia

19th April, 2021

Medovate’s recent e-ESRA congress symposium ‘Mitigating for Nerve Injury by Innovation’ was a reminder that both improvements in patient safety and total cost optimisation are important considerations when introducing new technology to regional anaesthesia (RA). Sales and Marketing Director at Medovate, Chris Rogers looks at the key symposium takeaways.


Medovate partners with Pharmamed to evaluate SAFIRA® in Slovenia

6th April, 2021

Medovate is delighted to be partnering with Pharmamed to evaluate SAFIRA® (SAFer Injection for Regional Anaesthesia) in one of the largest healthcare institutions in Slovenia.


Medovate partners with Vygon Vet to introduce pioneering technology to veterinary practice

4th March, 2021

Medovate is partnering with its UK distributor Vygon Vet to introduce its game-changing anaesthesia device SAFIRA® to veterinary practice.


Medovate Gold Sponsors of the 4th ESRA e-Congress

26th February, 2021

Medovate are pleased to be a gold sponsor at this year’s ESRA (European Society of Regional Anaesthesia & Pain Therapy) e-Congress taking place on Saturday 13th March 2021.


Medovate featured on first ever Healthcare Pavilion showcasing the best of UK healthcare on a global stage

22nd February, 2021

Medovate is delighted to be featured on the UK Healthcare Pavilion – the first ever UK-wide portal to showcase the UK healthcare and life sciences industry.


Implementation study reveals efficacy of Medovate’s novel HME safety device

19th February, 2021

A new study examining the performance of Medovate’s novel HME safety device in simulated clinical settings confirms proof of principle of the HUMIDICARE® engineered device. The novel HME provides warning of the error of dual humidification in a mechanical ventilation circuit.


Medovate unites with Konica Minolta Healthcare Americas Inc. to promote best practice in regional anaesthesia

28th January, 2021

Medovate has announced a newly formed partnership with Konica Minolta Healthcare Americas, Inc. to promote best practice within regional anaesthesia across the United States and the Middle East.


Meet Medovate at this year’s virtual Winter Scientific Meeting

6th January, 2021

Medovate are pleased to announce that we will be supporting as a Bronze Sponsor the Winter Scientific Meeting 2021 (WSM 2021), which is being held as a fully virtual event for the very first time on Wednesday 13th – Thursday 14th January 2021. Hosted by the Association of Anaesthetists, the event is the UK's biggest annual anaesthetic and peri-operative medicine conference.


Celebrating Medovate’s successes during a year of unpredictability

18th December, 2020

Chris Rogers, Sales & Marketing Director at Medovate shared a review of 2020 from Medovate's perspective on LinkedIn - read it here.


Medovate Christmas Opening Hours 2020

17th December, 2020

The Medovate Offices will be closed from 12 noon on Thursday, 24th December and will re-open on Monday 4th January 2021.


Medovate announces new agreement with Mercury Medical® securing 100% distributor coverage for SAFIRA™ in the USA

15th December, 2020

Medovate is proud to announce conclusion of an agreement with Mercury Medical to distribute its medical device SAFIRA™ (SAFer Injection for Regional Anesthesia) – a move that will now provide 100% coverage across the United States of America.


Medovate secures TGA Approval in Australia and inclusion on WAND Database in New Zealand for SAFIRA™

9th December, 2020

Medovate and its Brisbane-based distributor LTR Medical have announced they have secured both TGA (Therapeutic Goods Administration) Approval in Australia and inclusion on the WAND Database in New Zealand for their game-changing SAFIRA™ (SAFer Injection for Regional Anaesthesia) technology.


Medovate’s SAFIRA® named “Best Regional Anaesthesia Safety Solution 2020” at Healthcare and Pharmaceutical Awards

25th November, 2020

Medovate's game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia) named "Best Regional Anaesthesia Safety Solution 2020" in the GHP Healthcare and Pharmaceutical Awards


Medovate signs exclusive agreement with Sela Medical Ltd to distribute SAFIRA™ across Israel

3rd November, 2020

Medovate signs an exclusive agreement with Sela Medical Ltd to distribute SAFIRA™ (SAFer Injection for Regional Anaesthesia) across Israel.


Medovate signs exclusive agreement with Vygon to distribute regional anaesthesia device

19th October, 2020

Medovate and Vygon Group announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.


Medovate’s SAFIRA® featured in Journal of Anaesthesia Practice

28th September, 2020

Medovate’s game-changing SAFIRA® (SAFer Injection for Regional Anesthesia) has been featured in the Journal of Anaesthesia Practice. The article, written by Dr Stewart Southey, looks at how the COVID-19 pandemic has challenged the very nature of anaesthesia services, and the need for increased attention on patient safety in regional anaesthesia.


Medovate’s game-changing anaesthesia device SAFIRA® receives European CE regulatory approval

15th September, 2020

Medovate – a pioneering medical device development company specialising in anaesthesia, airway management, critical care, and surgery – announced it has received CE Mark Approval for its game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia).


Medovate announces distribution agreement with LTR Medical for sales of SAFIRA® in Australia and New Zealand

8th September, 2020

Medovate has concluded a distribution agreement with Brisbane-based LTR Medical which will provide exclusivity for SAFIRA® in Australia and New Zealand.


Medovate named ‘2020’s Leading Innovators in Medical Device Development – the UK’

1st September, 2020

Cambridge-based medical device company Medovate has been named ‘2020’s Leading Innovators in Medical Device Development’ in Global Health & Pharma’s (GHP) 2020 Global Excellence Awards.


Medovate PPE Face Masks used by Motor Sport Medical Response Unit at British Grand Prix

11th August, 2020

Face masks designed by Medovate and donated to a motor sport medical response unit have been used at the 70th Anniversary British Grand Prix.


Medovate secures exclusive partnership with TLC Medical to extend launch of innovative technology SAFIRA™ across the United States

29th July, 2020

Medovate has concluded an agreement with Iowa based TLC Medical to act as an additional exclusive distributor for its FDA cleared SAFIRA™ (SAFer Injection for Regional Anaesthesia) innovation in the United States of America.


Medovate to support winners of NHS innovation competition

16th July, 2020

Medovate are supporting two winning entries from the latest Health Enterprise East Innovation Voucher Competition. Both winning entries have come from clinicians working at the West Hertfordshire Hospitals NHS Trust; Consultant Anaesthetists, Dr. Beena Parker and Dr. Rajesh Shankar.


Medovate supports 'Innovate Now' NHS fundraising effort

8th July, 2020

Medical device company Medovate Ltd, is the first business to answer the call to donate to a new fund to support NHS innovation.


Medovate Announces Patent Grant for Innovative HME Device

22nd June, 2020

Medical device company Medovate Ltd has announced achieving successful grant of a UK patent for their HUMIDICARE® technology.


Medovate partners with NYSORA for launch of innovative regional anesthesia solution SAFIRA™ across the United States

2nd June, 2020

Medovate has announced that they will be partnering with the New York School of Regional Anesthesia (NYSORA) to support the launch of SAFIRA™, their innovation for regional anesthesia in the United States.


Medovate developing new PPE face mask to help front line clinicians with coronavirus

30th April, 2020

Medovate is developing an innovative face mask incorporating a specialised filter which has been proven to be an effective barrier against viruses.


Medovate secures exclusive partnerships with USA distributors to launch regional anaesthesia innovation SAFIRA

14th April, 2020

Medovate has concluded agreements with three USA-based companies to act as the exclusive distributors for its innovative medical technology for regional anaesthesia, SAFIRA (Safer Injection for Regional Anaesthesia) across the United States of America.


Onyx Health to support Medovate with US launch of SAFIRA for regional anaesthesia

9th April, 2020

Medovate are working with healthcare marketing communication specialists Onyx Health to prepare for the upcoming launch of their revolutionary SAFIRA technology for regional anaesthesia in the United States.


Medovate to bring life-saving upper GI therapy device to market

23rd March, 2020

Medovate has secured the exclusive rights to bring to market a pioneering endoscopic surgical device. The new device, ENDOVAC, has the potential to dramatically improve survival of patients with life threatening infection following a leak from their the upper gastrointestinal (GI) tract whilst significantly enhancing current treatment methods.


Medovate remains fully operational during COVID-19 pandemic

19th March, 2020

​During the current situation concerning the COVID-19 pandemic, we would like to reassure you that you can continue to contact Medovate as normal as our team are working from home. Click to read full details of how we are remaining operational and how to contact the Medovate team during this time.


Medovate unveils US launch plans for regional anaesthesia innovation

4th February, 2020

Medovate is breaking into the US market with the launch of the FDA approved SAFIRA regional anaesthesia innovation, at ASRA 2020 (the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting), taking place in San Francisco on the 23rd - 25th April. In addition to this, Medovate has also joined the Association of British Healthcare Industries (ABHI) US Accelerator.


Medovate continues growth with significant office expansion

29th November, 2019

Exactly two years since launch, Medovate, the medical device development company, is excited to be moving into its next chapter of growth with a relocation that will increase its capacity dramatically.


Medovate appoints new Sales and Marketing Director to showcase medtech innovations

11th October, 2019

Medovate, the medical device development company, is pleased to announce the appointment of Chris Rogers as its new Sales and Marketing Director.


Medovate Official Executive Partner of World Airway Management Meeting 2019

4th October, 2019

Medovate will be exhibiting and sponsoring a workshop session at the second World Airway Management Meeting (WAMM) taking place at the Amsterdam Conference Centre Beurs van Berlage on 13th – 16th November 2019 as an official Executive Partner of the event.


Medovate to demonstrate revolutionary new devices at world's largest international healthcare event

4th October, 2019

Medovate will be showcasing two exciting innovative medical technologies at Medica 2019 in Düsseldorf on 18 - 21 November 2019.


Medovate named 'most innovative medical device development company' in eastern England

24th September, 2019

Medovate, the Cambridge-based medical device company has been named ‘Most Innovative Medical Device Development Company’ in Eastern England in Global Health & Pharma’s (GHP) 2019 Healthcare and Pharmaceutical Awards.


Patient safety at forefront of two new medical devices for Regional Anaesthesia

6th June, 2019

Medovate is developing two new medical devices to improve patient safety and reduce the risk of nerve damage during regional anaesthesia procedures. As part of the process they have engaged the services of a leading manufacturer of educational tools for ultrasound guided interventional procedures to complete comprehensive simulated usability testing.


Medovate to License Innovative HME Device to Prevent Fatal Errors in Intensive Care

8th May, 2019

Medical device company, Medovate, has secured the exclusive rights to develop and market an innovative safety Heat and Moisture Exchanger (HME), a life-saving breathing apparatus designed to prevent critical airway obstruction, a medical ‘never event’.


Medovate achieves International Medical Devices Quality System Accreditation

2nd April, 2019

Medovate, the medical device company, has today announced it has achieved ISO 13485:2016 quality management system certification.


Medovate to develop radical new life-saving intensive care innovation

5th February, 2019

Medical device development company, Medovate, has today announced that it has secured the exclusive rights to design, develop, and manufacture Arterial Glucosave, a pioneering life-saving solution for arterial line procedures.


Medovate secures licence to develop and launch ground-breaking anaesthesia innovations

10th December, 2018

Dedicated to the development and commercialisation of medical technologies, Medovate is pleased to announce it has secured the exclusive rights to design, develop, manufacture and sell two ground-breaking innovations in the field of anaesthesia.


Medovate pleased to support MedTech Futures Conference

20th November, 2018

Recently held at the Wellcome Trust, Genome Campus, Hinxton Hall, Cambridge, Medovate were pleased to support the Medtech Futures conference hosted by Health Enterprise East, (HEE).